CytomX Therapeutics, Inc. (CTMX) is an American integrated oncology organization located in South San Francisco, California. The Company pioneered a novel class of antibody therapeutics called Probody therapeutics for the treatment of cancer.
Founded in 2008, CytomX started with a vision to transform lives with safer, more effective therapies. Since then, the company has developed a technology platform that offers innovative solutions to previously insoluble problems in oncology, driven by a unique company culture that fosters innovation and seeks mechanisms to solve critical healthcare needs.
The core of CytomX's techniques revolves around Probody therapeutics, a new class of treatment modalities designed to exploit the unique conditions of the tumor microenvironment. Probody therapeutics have been designed to stay inactive in healthy tissues but activate in the diseased tissue. This approach offers the ability to enhance the therapeutic index of antibody therapeutics and drug conjugates, significantly improving safety and efficacy.
CytomX's method has the potential to make a meaningful difference for patients by addressing the limitations of existing cancer therapies. Utilizing this powerful Probody platform, CytomX has moved quickly to produce a robust pipeline of therapies directed against clinically validated targets as well as novel oncology targets.
Its lead program, CX-072, a PD-L1 targeting Probody therapeutic, is in a Phase 2 clinical trial in combination with ipilimumab and in Phase 1b/2 for multiple cancer types. The Company also has strategic collaborations with industry giants like Bristol-Myers Squibb and Amgen to broaden its reach and enhance its products.
With its groundbreaking technology, dynamic pipeline, and strategic collaborations, CytomX Therapeutics, Inc. has firmly positioned itself at the forefront of next-generation antibody therapeutics. It continues to strive towards its mission of transforming lives with safer, more effective therapies.
And while there’s still much work to be done, the potential of what lies ahead remains very promising with CytomX. The company is continuously making efforts to fullfil its mission by exploring new therapeutic targets and nurturing beneficial relationships with strategic partners. Beyond the pipeline, it pursues continuous innovation, aiming to make significant impacts on global health.